Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Purple Biotech ( (PPBT) ).
Purple Biotech on March 18, 2026 reported that it has issued an updated March 2026 corporate presentation outlining progress across its immuno-oncology pipeline and platform. The company highlighted its CAPTN-3 conditionally activated tri-specific antibody platform, led by IM1240 for solid tumors, which is entering IND-enabling toxicology in 2026 and is expected to start a Phase 1 trial in 2027, while a second candidate, IM1305, advances preclinically.
The presentation also emphasized two Phase 2 clinical assets, CM24 in pancreatic cancer and NT219 in head and neck cancer, which are positioned for partnering and have additional data expected in 2026. Purple Biotech said it had $9.5 million in cash as of December 31, 2025, providing runway into the first half of 2027 to reach key milestones, a timetable that could influence its partnering strategy and potential value inflection points for shareholders in the coming year.
The most recent analyst rating on (PPBT) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, widening losses, and continued cash burn alongside a shrinking equity base). Technicals are also bearish with negative momentum and price below key moving averages, only partially offset by oversold signals. Valuation contributes little support due to unprofitability and no dividend data.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage immuno-oncology company listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker PPBT. The Israel-based firm focuses on multi-specific antibody platforms and oncology drug candidates targeting solid tumors, with key programs including IM1240, IM1305, CM24 and NT219, and a market focus on advanced cancer indications.
Average Trading Volume: 13,106
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.99M
For detailed information about PPBT stock, go to TipRanks’ Stock Analysis page.